119 related articles for article (PubMed ID: 32091270)
1. The prognostic impact of tumour NSD2 expression in advanced prostate cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Garstka N; Grubmüller B; Haitel A; Enikeev DV; Glybochko PV; Kramer G; Susani M; Shariat SF
Biomarkers; 2020 May; 25(3):268-273. PubMed ID: 32091270
[No Abstract] [Full Text] [Related]
2. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
3. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
[TBL] [Abstract][Full Text] [Related]
4. Association of WHSC1/NSD2 and T-cell infiltration with prostate cancer metastasis and prognosis.
Li Q; Zhu J; Zhang Y; Pan Y; Li Z; Wang M; Gao Y; Feng D; He X; Zhang C
Sci Rep; 2023 Dec; 13(1):21629. PubMed ID: 38062230
[TBL] [Abstract][Full Text] [Related]
5. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
6. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.
Zhang H; Qi C; Wang A; Yao B; Li L; Wang Y; Xu Y
J Exp Clin Cancer Res; 2013 Oct; 32(1):77. PubMed ID: 24422979
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
8. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.
Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F
Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563
[TBL] [Abstract][Full Text] [Related]
9. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Mortezavi A; Salemi S; Rupp NJ; Rüschoff JH; Hermanns T; Poyet C; Randazzo M; Simon HU; Moch H; Sulser T; Wild P; Eberli D
Oncotarget; 2017 May; 8(19):31765-31774. PubMed ID: 28423666
[TBL] [Abstract][Full Text] [Related]
10. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
12. NSD2 is a conserved driver of metastatic prostate cancer progression.
Aytes A; Giacobbe A; Mitrofanova A; Ruggero K; Cyrta J; Arriaga J; Palomero L; Farran-Matas S; Rubin MA; Shen MM; Califano A; Abate-Shen C
Nat Commun; 2018 Dec; 9(1):5201. PubMed ID: 30518758
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
16. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.
Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer.
Niu Y; Zhang L; Bi X; Yuan S; Chen P
Urol J; 2016 Mar; 13(1):2527-32. PubMed ID: 26945657
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Serum prosaposin levels are increased in patients with advanced prostate cancer.
Koochekpour S; Hu S; Vellasco-Gonzalez C; Bernardo R; Azabdaftari G; Zhu G; Zhau HE; Chung LW; Vessella RL
Prostate; 2012 Feb; 72(3):253-69. PubMed ID: 21630292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
